Discovery and Structure‐Activity Relationship Study of Pyrazolyl Indolenine Derivatives as Staphylococcus aureus Biofilm Inhibitors
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.70126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Jason Jonah James und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nanotechnology and Catalysis Research Centre, Institute for Advanced Studies, Universiti Malaya, Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Biofilms, Anti-Bacterial Agents, Methicillin-Resistant Staphylococcus aureus, Pyrazoles. Die Arbeit nennt 61 Literaturangaben. Gefördert von: This study was financially supported by the Ministry of Higher Education, Malaysia, for niche area research under the Higher Institution Centre of Excellence (….
Abstract (Originalsprache)
Staphylococcus aureus ‐associated infections pose a significant clinical challenge due to biofilm formation, which contributes to antibiotic resistance and persistent infections. The prevalence of methicillin‐resistant S. aureus (MRSA) further exacerbates this issue, underscoring the urgent need for effective therapeutic strategies. In this study, we report a potent and selective second‐generation MRSA biofilm inhibitor ( 4ad ), which showed a minimum biofilm inhibition concentration (MBIC 50 ) of 0.78 µg/mL and demonstrated ≥ 128‐fold selectivity for biofilm inhibition over planktonic growth. Through structural optimisation and fragmentation, we further identified a truncated analogue ( 5a ) that effectively eradicated a preformed MRSA biofilm, with a minimum biofilm eradication concentration (MBEC 50 ) of 0.78 µg/mL—outperforming both the first‐generation hit ( 4e ) and the clinically used antibiotics oxacillin and vancomycin. Notably, both 4ad and 5a exhibited no significant impact on planktonic bacterial viability or Vero cell cytotoxicity. Given the broad‐spectrum antibiofilm activity of 4e against S. aureus , we investigated its combinatorial effects with antibiotics. 4e demonstrated additive effects in combination with vancomycin, erythromycin, and amoxicillin. Importantly, both structure–activity relationship (SAR) and quantitative structure–activity relationship (QSAR) analyses identified key structural features associated with antibiofilm activity. Collectively, these findings support further development of pyrazolyl indolenine derivatives and mechanistic studies aimed at combating antibiotic‐resistant S. aureus biofilm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nanotechnology and Catalysis Research Centre, Institute for Advanced Studies, Universiti Malaya, Kuala Lumpur, Malaysia.
- Department of Medical Microbiology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
- Sekolah Tinggi Ilmu Farmasi Riau, Pekanbaru, Indonesia.
- Department of Molecular Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
ORCID-Profile: Jason Jonah James, Neni Frimayanti, Chin Fei Chee
Förderung
- This study was financially supported by the Ministry of Higher Education, Malaysia, for niche area research under the Higher Institution Centre of Excellence (…
Zitieren
APA
James, J. J., Yap, C. H., Frimayanti, N., Rashid, N. N., Tay, S. T., & Chee, C. F. (2025). Discovery and Structure‐Activity Relationship Study of Pyrazolyl Indolenine Derivatives as Staphylococcus aureus Biofilm Inhibitors. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70126
Vancouver
James JJ, Yap CH, Frimayanti N, Rashid NN, Tay ST, Chee CF. Discovery and Structure‐Activity Relationship Study of Pyrazolyl Indolenine Derivatives as Staphylococcus aureus Biofilm Inhibitors. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70126
BibTeX
@article{James2025,
author = {James, Jason Jonah and Yap, Cheng Hong and Frimayanti, Neni and Rashid, Nurshamimi Nor and Tay, Sun Tee and Chee, Chin Fei},
title = {Discovery and Structure‐Activity Relationship Study of Pyrazolyl Indolenine Derivatives as Staphylococcus aureus Biofilm Inhibitors},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.70126}
}
EUVIMED